|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.82 HKD | +2.51% |
|
+14.06% | -20.08% |
| Apr. 22 | Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine | MT |
| Apr. 22 | Cansino Biologics Pneumococcal Vaccine's Phase I Trial Offers Positive Results | MT |
CanSino Biologics Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was CNY 357.08 million compared to CNY 1,034.6 million a year ago. Net loss was CNY 1,447.3 million compared to CNY 909.43 million a year ago.
Basic loss per share from continuing operations was CNY 5.87 compared to CNY 3.68 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -20.08% | 1.1B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.35B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
CANSINO BIOLOGICS INC. 
